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Abstract 
 
Background: As a serious neuropsychiatric disease, hepatic encephalopathy (HE) is a clinical condition with 
several types regarding chronicity and clinical diversity that can develop as a complication of both acute and 
chronic liver failure. This study evaluates changes in thioacetamide (TAA)-induced acute hepatic encephalopathy 
(AHE) in rat as an animal model. 
 
Methods: Both genders of C57BL6, BALB/C mice and Sprague Dawley rats; (10 animals in each group) were 
compared for induction of AHE to clarify which animal and gender were appropriate. The animals (10 male 
rats in each group) were categorized in 4 groups according to the dose of the TAA administered (200, 300 and 
400 mg/kg of TAA at 24 h intervals for 4 days). A control group was treated with solvent of TAA which was 
water (5 ml/kg/day). The behavioral, biochemical markers of hepatic failure and histological aspects of thio-
acetamide (TAA) induced AHE and the correlation between the clinical severity and liver failure biomarkers 
were evaluated. 
 
Results: Rat was shown to be an animal model of choice for AHE while the optimum dosage of TAA to induce 
AHE was 300 mg/kg/day at 24 h intervals for 4 days. The behavioral score was partially correlated with the rising 
of some biomarkers and pathological findings.    
 
Conclusion: Rat can be introduced as the animal of choice for AHE to study the pathophysiology, pharmacology 
and the survival rate of disease in liver transplant patients. 
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Introduction 
 
Hepatic encephalopathy (HE) is a clinical condition 
with several types regarding chronicity and clinical 
diversity.
1 This syndrome can develop as a compli-
cation of both acute and chronic liver failure.
1,2 The 
wide spectrum of the clinical presentations add to 
the complexity of HE.
3,4 Meanwhile the burden of 
the disease on patients, family and health organiza-
tion is still high.
5 
To include both types of hepatic abnormality and 
the characteristics of the neurological manifestations, 
a multiaxial definition has been accepted.
2 According 
to this definition, type A represents HE in patients 
with acute liver failure (ALF), type B is rare and was 
defined to be the neuropsychiatric complication of 
portal-systemic bypass without any intrinsic hepatocel-
lular pathology and type C is the involvement of the 
brain seen in cirrhotic patients.
6  
Encephalopathy is a hallmark symptom in patients 
suffering from acute liver insufficiency and may pro-
gress from altered mental status to coma within days.
2 
There is a very high rate of mortality in this type.
7-9 
Supportive care until spontaneous recovery is the on-
ly treatment strategy but does not occur in many pa-
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tients.
9,10 To prevent death, liver transplantation is the 
only effective approach. In practice, however; due to 
little time to prepare the patient and liver for trans-
plantation, the death can occur.
6 This could be a prob-
lem even for a well-known transplant center as the 
center in Shiraz Nemazee Hospital.
11,12 
In contrast to type A, type C does not cause the 
patient’s demise although it carries a poor progno-
sis.
3,13 Therefore, a novel treatment for acute hepatic 
encephalopathy seems necessary to increase the sur-
vival of patients and improve the prognosis. Studies 
of the pathogenesis of human disorders have been 
significantly improved by utilization of animal mod-
els, by developing pharmco-therapeutic agents as the 
background of future clinical trials.
4 
Based on International Society for Hepatic En-
cephalopathy and Nitrogen Metabolism (ISHEN)
14 
recommendations, a toxin model of type A hepatic 
encephalopathy was selected using thioacetamide 
(TAA). The model is very similar to human acutely 
progressive hepatic disorders with the parallel in-
volvement of the brain.
14 Thioacetamide causes 
hepatocellular necrosis, bridging necrosis and lym-
phocytic infiltrate without any cholestasis. This 
model has been used to clarify changes in the func-
tions of the CNS in HE.
7,15 This study determines the 
behavioral, biochemical and histological aspects of 
acute hepatic encephalopathy in rat as an animal 
model of the disease. 
 
 
Materials and Methods 
 
We designed a systematic animal study to find out 
which laboratory rodent and gender and what doses 
of TAA were practically more appropriate to in-
duce acute hepatic encephalopathy (AHE). In phase 
1; 3 available species of rodents (C57BL6, 
BALB/C mice and Sprague Dawley rats; 10 ani-
mals in each group) were used for induction of 
AHE to clarify which one was the best animal of 
choice. The dosage of TAA was selected according 
to the literature
 (300 mg/kg/day at 24 h intervals for 
4 days).
12 The animals received intraperitoneal in-
jections of thioacetamide. The animals were kept at 
12 hours light and 12 hours darkness, temperature 
of 22°C, humidity of 30%. All animals had free 
access to food and water. All experimental animal 
protocols were approved by the Ethics Committee 
of Shiraz University of Medical Sciences. Animal 
selection, all experiments, subsequent care and the 
sacrifice procedure were all adhered to identical 
guidelines under supervision of Animal Care 
Committee of Iran Veterinary Organization. All 
experiments were carried out under aseptic condi-
tions in Laboratory Animal Center of Shiraz Uni-
versity of Medical Sciences. The induction rate and 
the mortality rate were recorded. The lowest moral-
ity rate was observed in Sprague Dawley rats after 
administration of TAA, so this species was selected 
for the next step of the experiment.  
In phase 2; to compare the effect of gender of rats 
in the modeling of AHE by TAA, both male and fe-
male genders of Sprague Dawley rats, weighing 180-
200 g were enrolled. The groups were compared for 
mortality rate and the clinical grading by the scoring 
method represented in Table 1. 
In phase 3; after selection of male gender as ap-
propriate one, different doses of the TAA were 
compared in male Sprague Dawley rats. The ani-
mals (10 male rats in each group weighing 180-200 
g) were categorized in 4 groups according to the 
dose of the TAA administered. Each group re-
ceived intraperitoneal injections of one of the three 
doses (200, 300 and 400 mg/kg) of TAA at 24 h 
intervals for 4 days. A control group was treated 
with solvent of TAA which was water (5 
ml/kg/day) (Table 2). The animals also received 
dextrose water and ringer lactate solutions (10 
mg/kg/day, IP) to prevent renal failure, hypogly-
cemia and electrolyte imbalance till the end of the 
experiment.  
Table 1: Clinical grading scores of the animals’ behavior.
Clinical grade  Definition
0 Normal  behavior 
1 Mild  lethargy 
2  Decreased motor activity, poor gesture control, 
diminished pain perception 
3  Sever ataxia, no spontaneous righting reflex 
4  No righting reflex, no reaction to pain stimuli 
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The animals were weighted and clinically evaluat-
ed in a daily manner. The onset of behavioral (clini-
cal) signs of encephalopathy in different TAA dosage 
groups were compared. In this phase, the mortality 
rate, the daily animal weight loss and the clinical 
grade were evaluated. On day 4, the blood samples of 
animal who survived the experiment were sent to la-
boratory for evaluation of biochemical markers of 
hepatic failure including alkaline phosohatase (ALP), 
alanine transaminase (ALT) and total bilirubin. Sam-
ples were also sent for determination of blood ammo-
nia level (NH4L) urgently. The livers were removed 
and transferred into 10% formalin for histological 
evaluations. 
In phase 4; 180-200 g male Sprague Dowley rats 
(N=45) were enrolled to induce AHE and were evalu-
ated for clinical grade of AHE and the correlation 
between this score and the biochemical markers and 
histological findings. So a dose of 300 mg/kg/day of 
TAA were administered for 4 days. On the 4
th day, 
the rats were divided into four groups in accordance 
with the attributed clinical grade. Blood samples were 
provided and the tests were repeated as mentioned in 
step 3. After scarification of the rats, livers were re-
moved and immediately placed in 10% neutral buff-
ered formalin. Tissues were then embedded in paraf-
fin and 5 μm thick sections were prepared, dehydrat-
ed and stained with hematoxylin and eosin and Mas-
son trichrome dyes. Two pathologists who were blind 
to the groups reported the results based on Bruck 
scoring method.
16 
SPSS software (Version 15, Chicago, IL, USA) 
was used for statistical analysis. Mortality was ex-
pressed as a percentage of the total group number for 
each treatment regime. ANOVA and Scheffe as post 
hoc analysis were used to determine any differences 
between groups after testing normality for each bi-
omarker. In the case that ANOVA showed statistical 
significance, the LSD procedure was used for indi-
vidual group comparison. Levels of significance were 
set at P<0.05. To examine the correlation between 
each biomarker and the clinical grade, Pearson corre-
lation test was implemented. 
Results  
 
In phase 1, the best animal species were enrolled 
which were able to tolerate the induction of AHE by 
TAA (300 mg/kg). The induction rate and the mortality 
rate in each group were presented in Table 3. 
 
Table 3: The induction and the mortality rates in 3 
species of rodents.
Species Induction 
rate (%) 
Mortality 
rate (%) 
Rats 80  10 
C57/BL6 mice  70  40 
BALB/C mice  80  50 
 
Due to lower mortality rate, Sprague Dawley rats 
were selected for the next step. In phase 2; both gen-
ders showed signs of encephalopathy and the rate of 
successful induction as well as mortality rate were 
similar. The mean clinical scores did not show any 
significant difference between male and female rats.  
In phase 3; for dose of 400 mg/kg; 70% of rats de-
veloped clinical score of 1 within 18 hours after the 1
st 
injection. In the two other TAA groups till 18 hours, 
the percent of induced rats presenting grade 1 were 
50% and 30% for 300 and 200 mg/kg respectively. In 
the 3
rd day post-induction, all three groups of TAA 
showed various higher grades of encephalopathy. 
The mortality rate in the group receiving 400 
mg/kg of TAA was unexpectedly high (40%). The 
mortality rate was 10% in both groups receiving 200 
and 300 mg/kg of TAA. In all groups, the laboratory 
data was taken only from survivors. The mean clini-
cal grade, biochemical markers for hepatic dysfunc-
tion, blood ammonium level and pathological scoring 
were represented in Table 4. 
The control group (not receiving TAA) was sig-
nificantly different with the induced groups (receiv-
ing different doses of TAA) regarding clinical 
scores, all biomarkers and histological findings. 
There was difference between clinical scores in in-
duction groups (induced by different dosages of 
TAA). Clinical scores of AHE group induced with 
Table 2: Groups receiving TAA or solvent in phase 3.
Group  TAA Dose (mg/kg)  No. Weight (Mean, g)   Gender
1   0   5  186  Male 
2 200  10  191.5  Male 
3 300  10  189.2  Male 
4 400  10  184.7  Male 
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200 mg/kg of TAA and higher doses (300 and 400 
mg/kg) were significantly different (p=0.029 and 
0.001 respectively), but there was no difference be-
tween the clinical scores in groups receiving 300 and 
400 mg/kg of TAA. As the mortality rate was lower 
in dose of 300 mg/kg of TAA group with better 
presentations of the signs and symptoms of AHE; this 
dosage was considered as the best dose for induction 
of AHE. 
Among TAA receiving groups, no difference was 
noticed in the level of SGOT and NH3. Although 
SGPT was not significantly different between 300 and 
400 mg/kg of TAA groups, there was a statistically 
significant lower level of SGPT in 200 mg/kg dose of 
TAA when compared with groups receiving higher 
doses. ALP raised with increase of the TAA dose. 
In phase 4; the AHE rats receiving 300 mg/kg of 
TAA were classified according to the attributed clini-
cal score defined in Table 1 (0-4). The frequency of 
scores in this phase was represented in Table 5.  
 
Table 5: The percent of scores in rats induced by 
TAA (300 mg/kg/day). 
Groups   Clinical score  Percent of score 
(%) 
1 (Non-
induced) 
0   9.1 
AHE 2  1  15.9 
AHE 3  2  34.1 
AHE 4  3  29.5 
AHE 5  4  11.4 
 
The biochemical markers and histological findings 
were compared between each arbitrary group. There 
was difference between group 1 (grade 0, non-
induced group) and all other groups (AHE groups 2-
5) in their average biomarkers (SGOT, SGPT, ALP 
and NH3). There was a difference between all groups 
(p=0.001 for SGOT and 0.004 for SGPT). Among the 
AHE groups, the only significant difference existed 
between AHE arbitrary groups 2 and 5, with clinical 
scores of 1 and 4 respectively (p=0.016 for SGOT 
and 0.026 for SGPT) (Table 6). 
 
Table 6: Correlation between each biomarker and 
the clinical grade in phase 4. 
Biomarker Correlation coefficient
SGOT 0.64 
SGPT 0.5 
ALP 0.38 
NH3 Level  0.83 
 
There was a difference between groups for alka-
line phosphatase (p=0.002). The difference was seen 
between non-induced group and AHE groups. Among 
the AHE groups, there were no significant differ-
ences. Regarding ammonium (NH3), there was a dif-
ference between groups (p=0.001). Among the AHE 
groups, the only significant difference existed be-
tween AHE groups 2 and 5, with clinical scores 1 and 
4 respectively (p=0.01). There were correlation be-
tween all biomarkers and the grade of the disease too. 
Histological findings showed inflammation and ne-
crosis in liver after administration of TAA in centri-
lobular form after 24 hours and extensive form after 48 
hours (Figure 1-5). As Table 7 shows, the dose of 300 
mg/kg of TAA was the best one to induce inflamma-
tion, necrosis and fibrosis in liver (AHE) of animals. 
 
 
Fig. 1: Control group receiving distilled water (x200, H&E). 
Table 4: The mean clinical grade, biochemical markers for hepatic dysfunction and blood ammonium level of 
survivor rats in each study group. 
Dose of TAA  Clinical score  NH3 level AlP SGOT SGPT
0 0  98.6  31    63  46.8 
200 0.89  1176.56  381  1328  433.33 
300 2.4    917.11  712.78  1249  858.56 
400 2.83  1183.5  896.33  1270  957.17 Farjam et al. 
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Fig. 2: Liver inflammation after administration of 200 
mg/kg of TAA (x200, H&E). 
 
 
Fig. 3: Extensive inflammation, necrosis and fibrosis 
in liver after administration of 300 mg/kg of TAA 
(x200, H&E). 
 
 
Discussion 
 
AHE is an emergency condition needing ICU care 
and is ended in death without liver transplantation.
2 
Designing clinical trials on AHE is not easy due to 
non-homogenous patients under study and little 
knowledge about the disease pathogenesis and non-
predictable clinical course.
2 Due to true practical need  
 
 
Fig. 4: Extensive inflammation, necrosis and fibrosis 
in liver after administration of 300 mg/kg of TAA 
(x200, Masson Trichrome). 
 
 
Fig. 5: Inflammation, necrosis and fibrosis in liver af-
ter administration of 400 mg/kg of TAA (x400, H&E). 
 
regarding studying the pathophysiology and pharma-
cology of acute hepatic encephalopathy, this systemat-
ic research on animal models was designed in the ani-
mal laboratory of Shiraz University of Medical Scienc-
es. Nemazee Hospital in Shiraz, Southern Iran affiliat-
ed to the university is the most important center for 
liver transplantation in the Middle East
2,3 and has in-
creased the survival of patients suffering from fulmi-
nant hepatic failure (FHF) to give them the opportunity 
Table 7: Histological findings after administration of different doses of TAA based on Bruck scoring method.
TAA 
Dose (mg/kg) 
Inflammation 
(0-3) 
Regional necrosis
(0-3) 
Extensive necrosis 
(0-3) 
Fibrosis
(0-3) 
200 1  1 1 0 
300 3  3  3  1 
400 2  2  2  1 
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of transplantation in a clinical priority. 
An animal model can be used for investigation of 
human diseases for a better understanding of the eti-
ology, pathogenesis, pathophysiology and pharma-
cology of the diseases without any risk of harm on 
actual human being during the process of research.
2 
Although not perfect,
2 the use of animal models helps 
the researchers to investigate disease status which 
might be inaccessible in diseased human.
2 Neverthe-
less, performing procedures on the laboratory animal 
imply harm to animal which is not ethical to imple-
ment on human.
3,4 
Our laboratory needed its own set up of the model 
to provide the researchers with some practical charac-
terization of the animal counterpart and getting more 
valid results in their researches on AHE. The estab-
lished model could be a basis for future studies on the 
disease.
17 From the ethical point of view, optimiza-
tion of the animal models can help in prevention of 
unnecessary animal death and so saving more labora-
tory animals.  Furthermore, some aspects of this study 
were novel. When considering the literature, there are 
no studies comparing different animal models. Due to 
lower mortality rate, Sprague Dawley rat was used to 
induce AHE which is superior to induction in mouse, 
either Albino or C57BL6. The monitoring of behavior 
is also easier in Sprague Dawley rats. The gender did 
not play any role in the induction rate of AHE in rats. 
The mortality rate in both sexes was not different. 
The best dose of the TAA to induce AHE was 300 
mg/kg/day for four days without losing a considerable 
number of animals for mortality. The majority of an-
imals presented the behavioral scores of 2 and 3 (Ta-
ble 5). It seems that there was no significant differ-
ence among the biological markers of hepatic insuffi-
ciency in different groups presenting different clinical 
scores. In other words, no liver marker can predict the 
prognosis and outcome of encephalopathy in the TAA 
model of AHE. Although in the rats presenting nor-
mal behavior (clinical score 0, group 1), the differ-
ence of biomarkers was significant in comparison 
with induced groups. Perhaps it could be explained 
that non-induced animals were relatively resistant to 
liver failure caused by TAA that can be a matter of 
further research. Also the rise in a few biomarkers in 
parallel to increase in behavioral score were noticed 
when the worst clinical condition (score 4) was com-
pared with the minimal behavioral disaster (score 1) 
even this was not consistently seen for all measured 
enzymes and markers. This finding was never report-
ed before in TAA induced AHE which is a known 
fact in human AHE demonstrating that the model was 
a good biochemical simulation of the human disease 
condition. There was a positive correlation between 
behavioral scores clinically and the level of bi-
omarkers in the blood. It might suggest that these bi-
ochemical markers can be followed as acceptable bi-
omarkers when the experimental drugs were tried on 
the model. The future studies on the model can be 
equipped with behavioral measurement by accepted 
behavioral systems to enrich the studies focused on 
encephalopathy. Neurophysiological and neuropatho-
logical assessment of the CNS of the induced rats can 
also be used in neuroscientific studies of AHE. The 
model can also be used for molecular, biological and 
immunological studies of the disease. Many neuro-
protective as well as hepatoprotective agents can be 
tried mechanistically as pharmacological tools. These 
approaches might sometimes fruit and the translational 
medicine based on the AHE model can practically help 
to increase their opportunity to survive till the appro-
priate liver could be donated for transplantation. 
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